Pharmaceutical

Atrial fibrillation market set to decline at a CAGR of 1.3% between 2022 and 2032

Atrial fibrillation drugs' patent expiration is largely responsible for the predicted decline in sales between 2022 and 2032

Jul 13, 2023 - 20:00
Atrial fibrillation market set to decline at a CAGR of 1.3% between 2022 and 2032
Atrial fibrillation drugs' patent expiration is largely responsible for the predicted decline in sales between 2022 and 2032
Read the original article

Tags:

Previous Article

Aridis’s AR-301 monoclonal antibody to receive FDA QIDP designation

Next Article

HTA outcomes in the 5EU are growing at 27% with a deep commitment to oncology

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

US Senate committee interrogates big pharma on “outrageously high” drug prices

US Senate committee interrogates big pharma on “outrage...

Feb 10, 2024

STAT+: Pear’s shadow effect: Data from a Medicaid digital health experiment does the policy rounds

STAT+: Pear’s shadow effect: Data from a Medicaid digit...

Sep 20, 2023

Navigating market access in Sweden

Navigating market access in Sweden

Aug 8, 2023